OmniAb, Inc. (OABI)
OABI Stock Price Chart
Explore OmniAb, Inc. interactive price chart. Choose custom timeframes to analyze OABI price movements and trends.
OABI Company Profile
Discover essential business fundamentals and corporate details for OmniAb, Inc. (OABI) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
30 Sept 2021
Employees
114.00
Website
https://www.omniab.comCEO
Matthew W. Foehr
Description
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
OABI Financial Timeline
Browse a chronological timeline of OmniAb, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.11, while revenue estimate is $4.69m.
Earnings released on 7 May 2026
EPS came in at -$0.06 surpassing the estimated -$0.10 by +40.00%, while revenue for the quarter reached $14.43m , beating expectations by +157.63%.
Earnings released on 4 Mar 2026
EPS came in at -$0.11 falling short of the estimated -$0.08 by -37.50%, while revenue for the quarter reached $8.38m , missing expectations by -6.97%.
Earnings released on 4 Nov 2025
EPS came in at -$0.14 falling short of the estimated -$0.14 by -2.94%, while revenue for the quarter reached $2.24m , missing expectations by -60.33%.
Earnings released on 6 Aug 2025
EPS came in at -$0.15 falling short of the estimated -$0.14 by -7.14%, while revenue for the quarter reached $3.90m , missing expectations by -30.95%.
Earnings released on 8 May 2025
EPS came in at -$0.17 matching the estimated -$0.17, while revenue for the quarter reached $4.15m , missing expectations by -7.45%.
Earnings released on 18 Mar 2025
EPS came in at -$0.12 surpassing the estimated -$0.13 by +7.69%, while revenue for the quarter reached $10.80m , beating expectations by +65.34%.
Earnings released on 12 Nov 2024
EPS came in at -$0.16 falling short of the estimated -$0.14 by -14.29%, while revenue for the quarter reached $4.17m , missing expectations by -58.81%.
Earnings released on 8 Aug 2024
EPS came in at -$0.13 surpassing the estimated -$0.18 by +27.78%, while revenue for the quarter reached $7.61m , beating expectations by +32.19%.
Earnings released on 9 May 2024
EPS came in at -$0.19 falling short of the estimated -$0.17 by -11.76%, while revenue for the quarter reached $3.80m , missing expectations by -35.22%.
Earnings released on 20 Mar 2024
EPS came in at -$0.14 surpassing the estimated -$0.17 by +17.65%, while revenue for the quarter reached $4.82m , missing expectations by -35.38%.
Earnings released on 9 Nov 2023
EPS came in at -$0.16 falling short of the estimated -$0.14 by -14.29%, while revenue for the quarter reached $5.48m , missing expectations by -46.98%.
Earnings released on 10 Aug 2023
EPS came in at -$0.15 falling short of the estimated -$0.11 by -36.36%, while revenue for the quarter reached $6.95m , missing expectations by -41.68%.
Earnings released on 11 May 2023
EPS came in at -$0.06 falling short of the estimated $0.05 by -220.00%, while revenue for the quarter reached $16.92m , missing expectations by -10.84%.
Earnings released on 30 Mar 2023
EPS came in at $0.07 surpassing the estimated $0.02 by +250.00%, while revenue for the quarter reached $35.35m , beating expectations by +26.15%.
Earnings released on 10 Nov 2022
EPS came in at -$0.02 surpassing the estimated -$0.04 by +43.65%, while revenue for the quarter reached $6.91m , meeting expectations.
Earnings released on 12 Aug 2022
EPS came in at -$0.09 , while revenue for the quarter reached $7.20m .
Earnings released on 20 May 2022
EPS came in at -$0.05 , while revenue for the quarter reached $9.62m .
Earnings released on 28 Mar 2022
EPS came in at -$0.00 , while revenue for the quarter reached $6.28m .
Earnings released on 25 Mar 2022
EPS came in at -$0.13 , while revenue for the quarter reached $21.56m .
OABI Stock Performance
Access detailed OABI performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
